All In Biotech

NDA 208352 · Evofem INC

Phexx

Citric Acid, Lactic Acid, Potassium Bitartrate · Vaginal

Last checked: Nov 19, 2026Latest source record: Apr 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 22, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

516

148 Phase 3, 44 recruiting

FAERS reports

181

71 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 2, 2025.

PHEXX is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. PHEXX is a combination of lactic acid, citric acid, and potassium bitartrate indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. ( 1 ) Limitations of Use: PHEXX is not effective for the prevention of pregnancy when administered after intercourse. Limitations of Use PHEXX is not effective for the prevention of pregnancy when administered after intercourse [ see Dosage and Administration (2.1) ].

Mechanism: In in vitro studies, PHEXX produced a normal vaginal pH range (pH 3.5 – 4.5) in the presence of semen. In clinical studies, post-coital testing demonstrated pH <5 in the majority of subjects, and sperm motility reduction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 22, 2020 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LabelLetterReview
1 products under this application
  • PHEXX · CITRIC ACID 1%; LACTIC ACID 1.8%; POTASSIUM BITARTRATE 0.4% · GEL, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Citric Acid" as an intervention, any sponsor and status, largest first.

All 516 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective59
  • pregnancy59
  • abortion spontaneous19
  • vulvovaginal burning sensation18
  • pregnancy on contraceptive14
  • product administration error14
  • complication of device insertion6
  • expired product administered6
  • nausea6
  • vaginal discharge6
  • vaginal haemorrhage6
  • abdominal pain5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
202136
202261
202335
202429
20258
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 506 on PubMed

Sponsor: Evofem INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.